Morphinhydrochlorid Retard Lannacher (Morphine Hydrochloride Trihydrate)

Morphine Hydrochloride, the active ingredient in Morphinhydrochlorid Retard Lannacher, is an opioid analgesic presented as an oral extended‑release formulation for oral use. It is employed to manage moderate to severe acute pain and chronic cancer‑related pain, particularly when other analgesics are insufficient. It is formulated for sustained plasma concentrations, allowing less frequent dosing compared with immediate‑release morphine products.

GNH USA supplies Morphinhydrochlorid Retard Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, oncology centres, pharmacies and clinics worldwide, with robust logistics and regulatory support for cross‑border procurement.

Morphine Hydrochloride is an opioid analgesic used in the management of pain. - Moderate to severe acute pain: provides rapid and sustained analgesia for postoperative, trauma‑related, or other acute painful conditions. - Chronic cancer pain: maintains continuous pain control in oncology patients with advanced disease. - Severe breakthrough pain: used as rescue medication when baseline extended‑release therapy is insufficient.

Morphine Hydrochloride may cause a range of adverse reactions, varying from common, mild effects to serious, potentially life‑threatening events.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure leading to dizziness or fainting. - Anaphylaxis: rare allergic reaction with rash, swelling, and airway compromise. - Adrenal insufficiency: rare endocrine disorder causing fatigue and low cortisol.

When prescribing or dispensing Morphinhydrochlorid Retard Lannacher, several precautions should be observed to ensure safe use. - Assess pain severity: confirm that opioid therapy is appropriate for the patient’s level of pain. - Monitor respiratory function: observe for signs of respiratory depression, especially during initiation or dose escalation. - Evaluate for opioid dependence: screen for history of substance abuse and consider risk mitigation strategies. - Adjust dose in renal or hepatic impairment: reduce dosage or increase dosing interval as clinically indicated. - Avoid concomitant CNS depressants: limit use with benzodiazepines, alcohol, or other sedatives. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Morphinhydrochlorid Retard Lannacher can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Respiratory depressants (e.g., benzodiazepines): may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): risk of severe central nervous system effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase morphine plasma concentrations. - Alcohol: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine effectiveness. - Other opioids or opioid‑containing products: cumulative opioid effect increases risk of adverse events. - Anticholinergic agents: may exacerbate constipation.